Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice.

Youn JI, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI.

J Leukoc Biol. 2012 Jan;91(1):167-81. doi: 10.1189/jlb.0311177. Epub 2011 Sep 27.

2.

6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice.

Jeanbart L, Kourtis IC, van der Vlies AJ, Swartz MA, Hubbell JA.

Cancer Immunol Immunother. 2015 Aug;64(8):1033-46. doi: 10.1007/s00262-015-1702-8. Epub 2015 May 16.

3.

Myeloid-derived suppressor cells confer tumor-suppressive functions on natural killer cells via polyinosinic:polycytidylic acid treatment in mouse tumor models.

Shime H, Kojima A, Maruyama A, Saito Y, Oshiumi H, Matsumoto M, Seya T.

J Innate Immun. 2014;6(3):293-305. doi: 10.1159/000355126. Epub 2013 Oct 29.

PMID:
24192491
4.

Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.

Schlecker E, Stojanovic A, Eisen C, Quack C, Falk CS, Umansky V, Cerwenka A.

J Immunol. 2012 Dec 15;189(12):5602-11. doi: 10.4049/jimmunol.1201018. Epub 2012 Nov 14.

5.

Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice.

Abe F, Dafferner AJ, Donkor M, Westphal SN, Scholar EM, Solheim JC, Singh RK, Hoke TA, Talmadge JE.

Cancer Immunol Immunother. 2010 Jan;59(1):47-62. doi: 10.1007/s00262-009-0719-2. Epub 2009 May 18.

PMID:
19449184
6.

Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity.

Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA.

Blood. 2008 Apr 15;111(8):4233-44. doi: 10.1182/blood-2007-07-099226. Epub 2008 Feb 13.

7.

Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism.

Waight JD, Hu Q, Miller A, Liu S, Abrams SI.

PLoS One. 2011;6(11):e27690. doi: 10.1371/journal.pone.0027690. Epub 2011 Nov 16.

8.

Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.

Schouppe E, Mommer C, Movahedi K, Laoui D, Morias Y, Gysemans C, Luyckx A, De Baetselier P, Van Ginderachter JA.

Eur J Immunol. 2013 Nov;43(11):2930-42. doi: 10.1002/eji.201343349. Epub 2013 Aug 25.

9.

Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis.

Waight JD, Netherby C, Hensen ML, Miller A, Hu Q, Liu S, Bogner PN, Farren MR, Lee KP, Liu K, Abrams SI.

J Clin Invest. 2013 Oct;123(10):4464-78. doi: 10.1172/JCI68189. Epub 2013 Sep 16.

10.

Serum inhibits the immunosuppressive function of myeloid-derived suppressor cells isolated from 4T1 tumor-bearing mice.

Hamilton MJ, Banáth JP, Lam V, Lepard NE, Krystal G, Bennewith KL.

Cancer Immunol Immunother. 2012 May;61(5):643-54. doi: 10.1007/s00262-011-1125-0. Epub 2011 Oct 22.

PMID:
22021068
11.

Blockade of Myd88 signaling induces antitumor effects by skewing the immunosuppressive function of myeloid-derived suppressor cells.

Hong EH, Chang SY, Lee BR, Kim YS, Lee JM, Kang CY, Kweon MN, Ko HJ.

Int J Cancer. 2013 Jun 15;132(12):2839-48. doi: 10.1002/ijc.27974. Epub 2012 Dec 19.

12.

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P.

Int Immunopharmacol. 2011 Jul;11(7):856-61. doi: 10.1016/j.intimp.2011.01.030. Epub 2011 Feb 11.

13.

Myeloid-derived suppressor cell functionality and interaction with Leishmania major parasites differ in C57BL/6 and BALB/c mice.

Schmid M, Zimara N, Wege AK, Ritter U.

Eur J Immunol. 2014 Nov;44(11):3295-306. doi: 10.1002/eji.201344335. Epub 2014 Sep 19.

14.

Tumor-induced myeloid-derived suppressor cell function is independent of IFN-γ and IL-4Rα.

Sinha P, Parker KH, Horn L, Ostrand-Rosenberg S.

Eur J Immunol. 2012 Aug;42(8):2052-9. doi: 10.1002/eji.201142230.

15.

Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts.

Maenhout SK, Van Lint S, Emeagi PU, Thielemans K, Aerts JL.

Int J Cancer. 2014 Mar 1;134(5):1077-90. doi: 10.1002/ijc.28449. Epub 2013 Sep 23.

16.

Granulocytic subset of myeloid derived suppressor cells in rats with mammary carcinoma.

Dolen Y, Gunaydin G, Esendagli G, Guc D.

Cell Immunol. 2015 May;295(1):29-35. doi: 10.1016/j.cellimm.2015.02.005. Epub 2015 Feb 18.

PMID:
25732602
17.

Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.

Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, Borrello I, Kato M, Schadendorf D, Baniyash M, Umansky V.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17111-6. doi: 10.1073/pnas.1108121108. Epub 2011 Oct 3.

18.

A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers.

Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY.

Clin Cancer Res. 2010 Sep 15;16(18):4583-94. doi: 10.1158/1078-0432.CCR-10-0733. Epub 2010 Aug 11.

19.

Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.

Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, Geilich M, Winkels G, Traggiai E, Casati A, Grassi F, Bronte V.

Eur J Immunol. 2010 Jan;40(1):22-35. doi: 10.1002/eji.200939903.

20.

Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells.

Lechner MG, Liebertz DJ, Epstein AL.

J Immunol. 2010 Aug 15;185(4):2273-84. doi: 10.4049/jimmunol.1000901. Epub 2010 Jul 19. Erratum in: J Immunol. 2010 Nov 1;185(9):5668.

Items per page

Supplemental Content

Write to the Help Desk